News Bayer Introduces Self-injecting Device to Help Growing Number of MS Patients in Middle East Bayer Introduces Self-injecting Device to Help Growing Number of MS Patients in Middle East by Patricia Silva, PhD | February 13, 2018 Share this article: Share article via email Copy article link An increaseĀ in multiple sclerosisĀ cases in the Middle East and North Africa has promptedĀ BayerĀ to introduce to the region an injector that patients can use to treat themselves. Researchers have suggested that increases in the region’s cases stem from many people adopting Western lifestyles, including smoking and using sun protection products, obtaining too little vitamin D, and being exposed to environmental problems like air pollution. Bayer said its auto-injector will be the first component of an innovative dose delivery system for MS. Patients can use it by itself or as part of a software-based system that keeps track of their injection history and allows them to share information with healthcare providers. The U.S. Food and Drug Administration approved a supplemental biologics license application inĀ 2017Ā for two Bayer products designed to help MS patients keep track of their injectionsĀ of Betaseron (interferon beta-1b. The approvals were forĀ myBETAappĀ and Betaconnect NavigatorĀ software. The navigator allows patients to use Bluetooth technology to connect their autoinjector to a Ā myBETAapp on their cellphone or laptop. The connection lets them share their injection information with their healthcare team. Patients can also manually enter injection information into the myBETAapp. āMultiple Sclerosis is a rising concern across the region,”Ā Jihad Inshasi said in a news release that Bayer provided to Multiple Sclerosis News Today. “It is a difficult condition to diagnose due to the complexity and variability of symptoms, which may vary from one person to the other. āBeing diagnosed with multiple sclerosis is a critical life event and can have a big impact on a patientās life,” he said. “However, with the new treatments in hand, patients can alleviate the conditions that arise from the disease” and doctors can “improve the quality of life of people living with this condition.ā Inshasi is a neurologist who directs the MS clinic at Rashid Hospital in Dubai. He is also a member of the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags Bayer, BETASERON, interferon beta-1b, prevalence
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression